CryptoBreaking News

Lincoln Pan, CEO at Jardine Matheson Holdings, discusses the group's strategic blueprint that includes a share buyback, boosting returns and adding exposure to developed markets. He speaks exclusively on "Bloomberg: The China Show."

Japan's central bank increased its benchmark interest rate to the highest since 1995 and signaled that further policy normalization lies ahead. Bloomberg's Shery Ahn reports from Tokyo.

Robert Kiyosaki renewed his support for Bitcoin (CRYPTO:BTC), Ethereum (CRYPTO:ETH), gold and other hard assets.

ARK Investment Management bought nearly 3.3 million shares of SpaceX across three exchange-traded funds after the company's Nasdaq debut.

Kalshi has introduced an artificial intelligence agent named Harrison to help assess and recommend new prediction markets.

XRP (CRYPTO:XRP) could attract a spot exchange-traded fund application from BlackRock, according to Digital Ascension Group Chairman Jake Claver, who linked the possibility to growing institutional interest in the XRP Ledger.

China's consumer spending contracted last month for the first time since the pandemic and investment deteriorated, exposing risks still facing the economy even as it benefits from booming exports and a deescalation in tensions around Iran. UBS Securities Chief China Economist Yu Song shares his analysis.

Bitcoin (CRYPTO:BTC) may have found a price floor near US$60,000, according to Coinbase Chief Executive Brian Armstrong, who said the cryptocurrency has likely bottomed after rebounding from a recent low of US$59,743.

Ventuals announced it is closing its project and shutting down its Hyperliquid-based perpetual markets, including contracts linked to the valuations of OpenAI and Anthropic.

Bybit introduced tokenised bond fund products through its RWA Earn platform, giving eligible users access to fixed-income investments managed by PIMCO and China Merchants Bank International.

Standard Chartered expects assets locked in decentralised finance to increase to US$2.7 trillion by the end of 2030, representing a 37-fold rise from current levels.

Biocon Executive Chairperson Kiran Mazumdar-Shaw says she is confident that the company's investment and capacity expansion in Insulin will make the company the top hub for the drug in the next five years. She speaks in an exclusive conversation with Bloomberg's Haslinda Amin.